Xconomy: Lightstone Closes $172M Fund for Early-Stage Biotechs
Summary
But Lightstone Ventures started up two years ago to throw its hat into the ring nonetheless, and now it’s got some dollars to put to work.One is Catabasis, the Cambridge-based startup developing triglyceride-lowering and anti-inflammatory drugs based on a technology that can combine two compounds with the help of a proprietary linker.Lightstone’s third investment is in Redwood City, CA-based EarLens, another medtech startup that’s developing a hearing device that uses light to transmit sound.General partners Mike Carusi, Chris Christoffersen, Jean George, and Hank Plain all spent more than a decade working together at the two firms.“We see tremendous opportunity in our focus areas thanks to a reinvigorated biotech and device IPO market, improvements at the FDA, greater clarity with the Affordable Care Act, and interest from the large corporate players to invest in and acquire innovative venture-backed companies,” Carusi said in a statement.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
